Across TCGA pan-cancer cohorts, TRAJ10 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TRAJ10 data layer compared with 15 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TRAJ10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAJ10 expression acts as an unfavorable survival marker.

HNSC are the cancer types where TRAJ10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.209	0.710	.032	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: TRAJ10 tumor-vs-normal RNA expression · all TRAJ10 data types